IMMUNOVX Trademark

Trademark Overview


On Tuesday, July 18, 2023, a trademark application was filed for IMMUNOVX with the United States Patent and Trademark Office. The USPTO has given the IMMUNOVX trademark a serial number of 98089376. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Thursday, October 17, 2024. The IMMUNOVX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Clinical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development and consultation related thereto in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of imm...
immunovx

General Information


Serial Number98089376
Word MarkIMMUNOVX
Filing DateTuesday, July 18, 2023
Status645 - FINAL REFUSAL - MAILED
Status DateThursday, October 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesClinical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development and consultation related thereto in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research consulting; Scientific research consulting in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Basic and clinical research in the field of respiratory science and medicine; Biochemical research and development; Consulting services for others in the field of design, planning, and implementation project management of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research information in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical research and development; Product research and development; Providing information about medical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Providing information about medical and scientific research; Providing medical and scientific research information; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Scientific study and research in the field of reproduction, husbandry, and general health of food-chain animals; Vaccine research and development; Vaccine research and development services

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, August 16, 2023
Primary Code042
First Use Anywhere DateSaturday, July 1, 2023
First Use In Commerce DateSaturday, July 1, 2023

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressConshohocken, PA 19428

Trademark Events


Event DateEvent Description
Friday, July 21, 2023NEW APPLICATION ENTERED
Wednesday, August 16, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 23, 2024ASSIGNED TO EXAMINER
Friday, September 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, March 23, 2024NON-FINAL ACTION WRITTEN
Saturday, March 23, 2024NON-FINAL ACTION E-MAILED
Saturday, March 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 10, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 17, 2024FINAL REFUSAL WRITTEN
Thursday, October 17, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, October 17, 2024FINAL REFUSAL E-MAILED
Friday, September 20, 2024ASSIGNED TO LIE